<DOC>
	<DOC>NCT00575874</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy response of rivoglitazone HCl compared to pioglitazone HCl on the placebo-corrected change from baseline in HbA1c after 12 weeks of treatment in patients with type 2 diabetes.</brief_summary>
	<brief_title>Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes HbA1c &gt;6.5% and &lt;10.0% FPG &gt;126 mg/dL (7 mmol/L) and &lt; 270 mg/dL (15 mmol/L) History of type 1 diabetes History of ketoacidosis Current insulin therapy Cpeptide &lt;0.5ng/mL Imparied hepatic function NYHA Class IIIV cardiac status or hospitalization for CHF or EF&lt;40% uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>rivoglitazone HCl</keyword>
	<keyword>pioglitazone HCl</keyword>
	<keyword>thiazolidinedione</keyword>
	<keyword>peroxisome proliferator-activated receptor gamma (PPAR gamma)</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>